hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06383871 id: HRS-7058-101 briefTitle: A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-06 date: 2026-06 date: 2024-04-25 date: 2024-04-25 name: Shandong Suncadia Medicine Co., Ltd. class: INDUSTRY briefSummary: This study is a multicentre, open phase I clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in subjects with advanced malignant tumour. To evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-7058. conditions: Advanced Malignant Tumour studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 151 type: ESTIMATED name: HRS-7058 capsule/ HRS-7058 tablet measure: Dose-limiting toxicity (DLT) measure: maximum tolerated dose (MTD) measure: Phase II recommended dose (RP2D) measure: Safety endpoints: adverse events (AE) measure: Efficacy endpoints: Objective response rate (ORR) assessed based on RECIST v1.1 criterion measure: Efficacy endpoints: duration of response (DoR) assessed based on RECIST v1.1 criterion measure: Efficacy endpoints: disease control rate (DCR) assessed based on RECIST v1.1 criterion measure: Efficacy endpoints: progression-free survival (PFS) assessed based on RECIST v1.1 criterion measure: Efficacy endpoints: overall survival (OS) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06383858 id: [2023] Ethics Review NO.151 briefTitle: The Project of Gestational Hypertension and Preeclampsia Screening and Prevention Center overallStatus: RECRUITING date: 2023-08-01 date: 2028-12-31 date: 2028-12-31 date: 2024-04-25 date: 2024-04-25 name: The Third Affiliated Hospital of Guangzhou Medical University class: OTHER briefSummary: Preeclampsia is the main cause of illness and death in pregnant women and fetuses. Currently, there is no effective treatment for preeclampsia in clinical practice, and the fundamental treatment is still termination of pregnancy and placental delivery.
Therefore, early prediction of preeclampsia and targeted strengthening of high-risk pregnant women supervision, early intervention and diagnosis and treatment can greatly reduce the serious obstetric complications and perinatal maternal and fetal deaths caused by preeclampsia, which has significant social and clinical significance. conditions: Preeclampsia conditions: Maternal Deaths studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50000 type: ESTIMATED measure: Preeclampsia measure: Premature birth measure: Fetal Growth Restriction measure: Severe complications of preeclampsia sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: FANG HE status: RECRUITING city: Guangzhou state: Guangdong zip: 510150 country: China name: FANG HE, M.D role: CONTACT phone: 13724831279 email: hefangjnu@126.com name: Qingwen Nie, Master role: CONTACT phone: 15622149953 email: qw0621n@163.com lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06383845 id: MAS ESLI briefTitle: Comparison of Erector Spinae Plane Block vs Intravenous Lidocaine for Chronic Pain Post Mastectomy. overallStatus: ACTIVE_NOT_RECRUITING date: 2023-01-01 date: 2024-01-31 date: 2024-09-30 date: 2024-04-25 date: 2024-04-25 name: University Tunis El Manar class: OTHER briefSummary: Patients undergoing breast surgery were divided into two groups: Intravenous Lidocaine (Lido-IV) vs Erector Spinae Block (ESP).
Persistant pain post mastectomy was assessed by SFM-PQ score at 1, 3 and 6 months post surgery. conditions: Breast Surgery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Erector spinae plane block VS intravenous lidocaine. primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 60 type: ESTIMATED name: Lido-IV name: ESP Block measure: Item 5 of Brief Pain inventory score (BPI Score) measure: Acute pain assessed by Simple Verbal Scale (SVS) measure: Postoperative nausea and vomiting measure: Hospital length of stay measure: DN4 questionnaire (DN4) measure: The short-form McGill Pain Questionnaire (SFM-PQ) sex: FEMALE minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tunisia city: Nabeul zip: 8000 country: Tunisia lat: 36.45606 lon: 10.73763 hasResults: False
nctId: NCT06383806 id: STU00219933 id: 315-SR-23 type: OTHER_GRANT domain: American Academy of Sleep Medicine Foundation briefTitle: Decreasing Nightmares in Adults With Narcolepsy acronym: DAWN overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2026-09 date: 2026-09 date: 2024-04-25 date: 2024-04-25 name: Northwestern University class: OTHER briefSummary: The purpose of this clinical trial is learn whether a behavioral (non-medication) treatment can reduce nightmares in adults with narcolepsy. All participants will receive the treatment and will complete three assessments. Half of the participants will receive the treatment after the first assessment, and half will receive it after the second assessment. conditions: Narcolepsy conditions: Narcolepsy Type 1 conditions: Narcolepsy With Cataplexy conditions: Narcolepsy Without Cataplexy conditions: Nightmare conditions: Nightmare Disorder With Associated Other Sleep Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Waitlist control primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Imagery Rehearsal Therapy (IRT) measure: Disturbing Dream and Nightmare Severity Index (DDNSI) measure: Nightmare frequency (sleep diary) measure: PROMIS Anxiety measure: PROMIS Depression sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06383793 id: Northjiangsu000 briefTitle: Comparative Analysis of Short-Term Therapeutic Effects Between the π-Shaped and Overlap Methods for Esophagogastrostomy in Totally Laparoscopic Total Gastrectomy overallStatus: RECRUITING date: 2024-04-01 date: 2024-08-30 date: 2025-12-30 date: 2024-04-25 date: 2024-04-25 name: Northern Jiangsu People's Hospital class: OTHER briefSummary: As of now, although the safety of π-shaped anastomosis and the overlap method has been separately discussed in different contexts, there have been few studies considering a direct comparison of the results of these two methods.
This article aims to explore the differences in the short-term therapeutic effects, surgical effectiveness, and safety between laparoscopic total gastrectomy with esophagogastrostomy using the overlap method and the π-shaped method. The goal is to provide new reference points for surgeons in the clinical decision-making process regarding the choice of anastomotic techniques during totally laparoscopic total gastrectomy. conditions: Gastric Cancer studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: RETROSPECTIVE count: 100 type: ESTIMATED name: overlap measure: 1 year survival sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yifan Cheng status: RECRUITING city: Yangzhou state: Jiangsu zip: 225000 country: China name: Yifan Cheng role: CONTACT phone: 8615267258283 email: cyfchengyifan528@sina.com lat: 32.39722 lon: 119.43583 hasResults: False
nctId: NCT06383780 id: SYSKY-2023-901-01 briefTitle: Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. overallStatus: RECRUITING date: 2024-05-01 date: 2027-05-01 date: 2027-05-01 date: 2024-04-25 date: 2024-04-25 name: XIANG YANQUN class: OTHER briefSummary: This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety of the GP（Gemcitabine combined with cisplatin） regimen in combination with Tislelizumab versus the TPC（cisplatin, nab-paclitaxel and capecitabine）regimen in combination with Tislelizumab for the first-line treatment of Nasopharyngeal Carcinoma patients With Bone Metastasis. conditions: Nasopharyngeal Carcinoma studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Active Comparator:Drug:GP（Gemcitabine combined with cisplatin）regimen combined with Tislelizumab Experimental:Drug：TPC（cisplatin, nab-paclitaxel and capecitabine）regimen combined with Tislelizumab primaryPurpose: TREATMENT masking: NONE count: 90 type: ESTIMATED name: GP combined with Tislelizumab name: TPC combined with Tislelizumab measure: 1-year progression-free survival rate measure: Overall survival measure: incidence of adverse events measure: rate of skeletal-related events measure: Biomarker response (EBV-DNA, bone metabolic markers) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: SunYat-senU status: RECRUITING city: Guangzhou state: Guangdong zip: 510060 country: China name: Yanqun Xiang, MD role: CONTACT phone: +86-18666096623 email: xiangyq@sysucc.org.cn name: Weixiong Xia, MD role: CONTACT phone: +86-18520415699 email: xiawx@sysucc.org.cn lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06383767 id: ESG401-301 briefTitle: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer overallStatus: NOT_YET_RECRUITING date: 2024-06-30 date: 2026-07-31 date: 2026-12-31 date: 2024-04-25 date: 2024-04-25 name: Shanghai Escugen Biotechnology Co., Ltd class: INDUSTRY briefSummary: The aim of this study is to evaluate the efficacy and safety of ESG401 in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer. conditions: Metastatic Breast Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 378 type: ESTIMATED name: ESG401 name: Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice) measure: Progression-free survival (PFS) assessed by IRC per RECIST 1.1 measure: Progression-free survival (PFS) assessed by the investigators per RECIST V 1.1 measure: Overall Survival (OS) measure: Objective Response Rate (ORR) measure: Clinical Benefit Rate (CBR) measure: Duration of Response (DoR) measure: Quality of life evaluated using the NCC-BC-A scale measure: Adverse events(AEs) and severe adverse events (SAEs) measure: Clearance measure: Volume of distribution measure: ADA sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cancer Hospital Chinese Academy of Medical Sciences city: Beijing state: Beijing zip: 100021 country: China name: Fei Ma, PhD role: CONTACT lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06383754 id: Clove briefTitle: Clareon Intraocular Lens Stability in Vitrectomy Patients: CLOVE Study overallStatus: COMPLETED date: 2021-06-07 date: 2024-03-08 date: 2024-03-15 date: 2024-04-25 date: 2024-04-25 name: The University of Hong Kong class: OTHER briefSummary: This prospective randomized controlled trial will be conducted to investigate Clareon intraocular lens (IOL) stability in vitrectomy patients. The investigator plans to target the patients undergoing cataract surgery. A randomized study will be conducted with 2 arms, one with Clareon IOL versus a second arm using the Tecnis 1 In this non-inferiority study, the investigator will compare Clareon IOL from Alcon with the existing Tecnis 1 IOL from Precision Lens which is the commonly used intraocular lens in combined vitrectomy cases in Hong Kong. conditions: Senile Cataract conditions: Epiretinal Membrane conditions: Vitreous Hemorrhage studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Patients are randomised and masked from the treatment whoMasked: PARTICIPANT count: 50 type: ACTUAL name: Clareon name: Tecnis 1 measure: Position stability of Clareon and Tecnis 1 IOL measure: Visual acuity measure: Refraction measure: Axial movement measure: Decentration measure: Compare intra operative and post operative complication sex: ALL minimumAge: 50 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Grantham Hospital city: Hong Kong country: Hong Kong lat: 22.27832 lon: 114.17469 hasResults: False
nctId: NCT06383741 id: 2023-00541 briefTitle: Predicting Outcomes in ICH Patients on Direct Factor Xa Inhibitors acronym: FIRE-Xa overallStatus: RECRUITING date: 2023-07-10 date: 2026-04-01 date: 2026-04-01 date: 2024-04-25 date: 2024-04-25 name: Insel Gruppe AG, University Hospital Bern class: OTHER briefSummary: This study focuses on direct factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) and the thrombin inhibitor dabigatran, commonly used for stroke prevention in atrial fibrillation. Despite lower intracranial bleeding risks with these drugs, around 0.2-1.0% of patients annually experience intracranial hemorrhage (ICH), predominantly intracerebral.
This research aims to bridge gaps in understanding factor-Xa inhibitor-related ICH, addressing both immediate and prolonged outcomes to enhance clinical decision-making. conditions: Intra Cerebral Hemorrhage studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED measure: Good functional outcome measure: Good functional outcome measure: Good functional outcome measure: Haematoma expansion measure: Number of patients with significant anticoagulant activity arriving late measure: Absolute haematoma expansion (in ml) between baseline and follow-up imaging measure: Symptomatic haematoma expansion measure: Resumption of anticoagulant therapy after haemorrhage measure: Patients living at home measure: Functionally independent patients (mRS 0-2) measure: Excellent outcome (mRS 0-1) measure: Arterial and venous events at 12 months sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Insel Gruppe AG, Inselspital Bern status: RECRUITING city: Bern zip: 3010 country: Switzerland name: David J. Seiffge, Prof. Dr. med. role: CONTACT phone: +41 31 664 05 09 email: david.seiffge@insel.ch name: Janis P. Rauch, PD Dr. med. role: CONTACT email: janispatricia.rauch@insel.ch lat: 46.94809 lon: 7.44744 hasResults: False
nctId: NCT06383728 id: ES-2024-014-02 briefTitle: Osimertinib as Neoadjuvant Therapy in Patients With Resectable Stage II-IIIB EGFR-mutated Lung Squamous Cell Carcinoma acronym: GALAXY-02 overallStatus: RECRUITING date: 2024-04-01 date: 2025-10-31 date: 2029-04-30 date: 2024-04-25 date: 2024-04-25 name: The First Affiliated Hospital of Guangzhou Medical University class: OTHER briefSummary: Previous trials, such as ADURA and CTONG, have demonstrated the benefits of neoadjuvant targeted therapy in patient with EGFR mutations , which can effectively reduce the extent of tumors and improve the survival outcomes. However, clinical trials of neoadjuvant targeted therapy in NSCLC have rarely enrolled patients with EGFR-mutated lung squamous cell carcinoma due to its rarity, which means that the safety and feasibility of neoadjuvant osimertinib in patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma remains relatively unknown. conditions: Lung Cancer conditions: Carcinoma, Squamous Cell studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma receive osimertinib (80mg/d, ≥9 weeks) primaryPurpose: TREATMENT masking: NONE count: 51 type: ESTIMATED name: Osimertinib measure: Objective Response Rate, ORR measure: Safety: frequency of severe adverse events measure: Major pathologic response, MPR measure: R0 rate measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Disease control rate (DCR) measure: Duration of remission (DOR) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Guangzhou Medical University status: RECRUITING city: Guangzhou state: Guangdong zip: 510120 country: China name: Shuben Li, Doctor role: CONTACT email: 13500030280@163.com lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06383715 id: 2024-624 briefTitle: Congitive Behavioral Therapy Workshop for Content Moderators overallStatus: RECRUITING date: 2024-05-01 date: 2024-06-01 date: 2024-08-01 date: 2024-04-25 date: 2024-04-26 name: Universidad Europea de Valencia class: OTHER briefSummary: Professional content moderators play a critical role in preventing Internet users from being exposed to more sensitive content. However, recent literature has shown that this work places content moderators at increased risk for several psychological outcomes, including intrusive thoughts and vicarious stress trauma. This pilot study will assess the acceptability and feasibility of a brief (4-session) cognitive-behavioral workshop to reduce these risks. conditions: Work-Related Condition conditions: Work-Related Stress Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Cognitive-Behavioral Therapy Workshop for Content Moderators measure: The Kessler Psychological Distress Scale (K10) measure: Work Satisfaction Scale, JobStat'73 measure: Coping Mechanisms Scale measure: PTSD Checklist-Civilian Version (PCL-C) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MEGA cloud services status: RECRUITING city: Salamanca zip: 37002 country: Spain name: Valentina Sirna role: CONTACT phone: +34 685 34 79 07 email: support@mega.nz name: Carlos López-Pinar, PhD role: PRINCIPAL_INVESTIGATOR lat: 40.96882 lon: -5.66388 hasResults: False
nctId: NCT06383702 id: HEX1939-002 briefTitle: Phase III Trial to Evaluate the Efficacy and Safety of Pregabalin in the Treatment of Painful Diabetic Peripheral Neuropathy overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2025-04-01 date: 2025-04-15 date: 2024-04-25 date: 2024-04-25 name: CSPC Ouyi Pharmaceutical Co., Ltd. class: INDUSTRY briefSummary: This study is designed to evaluate the efficacy and safety of pregabalin extended-release tablets in the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Pregabalin has been approved in more than 130 countries for neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and neuralgia associated with spinal cord injury. Pregabalin extended-release tablets were administered once daily, as a single dose after dinner. Compared with pregabalin capsule formulation, it reduces the frequency of medication and improves patient compliance. conditions: Neuropathic Pain Associated With Diabetic Peripheral Neuropathy studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel design primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 358 type: ESTIMATED name: pregabalin sustained-release tablets name: Placebo measure: NRS mean change at week 13 measure: NRS mean change at Weeks 1-12 and 14 measure: Proportion of subjects with NRS reduction measure: MOS-SS score measure: HADS score measure: PGIC score measure: CGIC score sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06383689 id: Az. 297/23-EP briefTitle: Placebo Optimization of the Presurgical Long-term Video-EEG Monitoring acronym: OPERA overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-04-30 date: 2026-12-31 date: 2024-04-25 date: 2024-04-25 name: University Hospital, Bonn class: OTHER briefSummary: The notion of genuine placebo effects on epileptic seizure events (i.e., effects beyond methodological study artifacts) is incompatible with the standard model of epilepsy seizure genesis. In this single-blind controlled study, the effectiveness of a covered placebo on (1) the timing of the occurrence of a first epileptic seizure ("seizure pill") versus (2) the subjective well-being ("comfort pill") during pre-surgical video-EEG monitoring will be examined. It is hypothesized that a placebo effect on subjective well-being can be demonstrated, but that epileptic seizure events are not influenced by placebo. conditions: Symptomatic Epilepsy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: monocentric single-blinded randomized clinical study on the effectiveness of covered placebo on epileptic seizure occurrence and emotional well-being with 3 study conditions: "seizure pill" (PCB-S), "well-being pill" (PCB-W) and no pill (control) primaryPurpose: BASIC_SCIENCE masking: SINGLE maskingDescription: Like in psychological studies, only patients can participate in the study who consent to accept that complete study information can only be provided after the entire study was finished (with an option to withdraw consent at that point) as information on ingredients of the study pill (which is placebo) must be concealed for inherent reasons (study on effects of covered placebo). whoMasked: PARTICIPANT count: 90 type: ESTIMATED name: Seizure placebo pill name: Well-being placebo pill measure: Latency to first epileptic seizure measure: Occurrence of an epileptic seizure measure: Early occurrence of an epileptic seizure within the first 72 hours measure: Number of epileptic seizures during the video-EEG measure: Number of early occurring epileptic seizures measure: Daily average frequency of epileptic seizures measure: Very early first epileptic seizure measure: Early epileptic seizure measure: Epileptic seizure within the first three days measure: Emotional well-being measure: Dissociative non-epileptic seizures sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Epileptology, University Hospital Bonn city: Bonn state: NRW zip: 53127 country: Germany name: Rainer Surges, Prof. role: CONTACT phone: +49 228 287-15727 email: rainer.surges@ukbonn.de name: Christian Hoppe, PD Dr. role: CONTACT phone: +49 228 287-16172 email: christian.hoppe@ukbonn.de lat: 50.73438 lon: 7.09549 hasResults: False
nctId: NCT06383676 id: 1 briefTitle: Effect Of Functional Balance Exercise İn Elderly acronym: RCT overallStatus: ACTIVE_NOT_RECRUITING date: 2023-04-20 date: 2024-11-30 date: 2025-05-30 date: 2024-04-25 date: 2024-04-25 name: Tarsus University class: OTHER briefSummary: The elderly population is increasing in Turkey and in the world. Many health problems, such as a decrease in physical and psychological abilities and an increase in chronic problems, occur with aging. It is important to encourage and support practices for the development of exercises to increase physical and cognitive capacity in order to early recognize and reduce the effects of problems that develop with aging. To the best of our knowledge, there is no exercise training to increase reaction time in the elderly in the literature. conditions: Older People conditions: Exercise studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study was planned as a randomized controlled study primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Study participants are unaware of their assigned group whoMasked: PARTICIPANT count: 28 type: ACTUAL name: Functional reaction balance training name: Functional balance training measure: The Montreal Cognitive Assessment (MoCA) measure: Stroop Test measure: The Simple Reaction Time measure: The Four Square Step Test (FSST) measure: The short physical performance battery (SPPB) measure: Timed Up and Go Test (TUG) measure: Falls Efficacy Scale ( FES) measure: Mini-BESTest: Balance Evaluation Systems Test sex: ALL minimumAge: 65 Years maximumAge: 85 Years stdAges: OLDER_ADULT facility: Fatma Kübra ÇEKOK city: Ankara zip: 06000 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False